CommercialCoverageMedium impact
11.15.16y, Vagus Nerve Stimulation (VNS)
Independence Blue Cross·Neurology, Neurosurgery, General Surgery·Medical Policy
Effective date
Oct 19, 2026
We identified it
Oct 20, 2026
Summary
Independence Blue Cross updated Medical Policy 11.15.16y effective 10/19/2026 to clarify that implantable VNS for upper-limb impairment due to stroke (MicroTransponder ViviStim system) is experimental/investigational and not covered. This policy change adds new FDA-approved technology to the non-covered list. Coverage remains in place only for medically refractory seizures when surgery is not recommended or has failed.
Action Required
Effective 10/19/2026: Billing team should update prior authorization workflows and claim submission protocols to deny or route for medical review any claims for implantable VNS using the MicroTransponder ViviStim system for upper-limb impairment due to stroke (regardless of FDA approval status). Verify that billing system alerts flag this specific indication as experimental/investigational for Independence Blue Cross Commercial members. Continue processing implantable VNS claims for medically refractory seizures per existing coverage criteria. Educate providers that FDA approval alone does not guarantee coverage; the Company maintains its own medical necessity determination separate from FDA status. Retain documentation of member denials for this indication for audit purposes.